We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Gilead Sciences has downgraded its development pact with Belgian drugmaker Galapagos after deciding to no longer pursue FDA approval for its rheumatoid arthritis (RA) drug Jyseleca (filgotinib). Read More
A coalition of hospital groups has filed a lawsuit alleging that HHS failed to ensure that drugmakers offer discounted medications to covered entity hospitals under the 340 drug discount program. Read More
Canada administered its first shots of Pfizer/BioNTech’s COVID-19 vaccine to frontline healthcare workers Monday as coronavirus vaccinations also got underway in the U.S. Read More
Boehringer Ingelheim (BI) is acquiring NBE-Therapeutics for $1.5 billion, adding to its cancer portfolio with novel antibody-drug conjugates (ADC). Read More
A conference the neuroscience biotech company Biogen held in a Boston hotel Feb. 26-27 appears to have been a “superspreader event” for COVID-19, ultimately leading to hundreds of thousands of cases, according to a new study. Read More
Gilead Sciences has announced plans to purchase German biotech firm MYR GmbH for an estimated $1.4 billion (€1.15 billion), with the potential for additional milestone-based payments of up to $364.3 million (€300 million). Read More
Atara will receive an initial $60 million from Bayer and is eligible to receive an additional $610 million and tiered royalties in milestone-based payments. Read More
With FDA emergency authorization seeming very likely for Pfizer’s COVID-19 vaccine within days, all 50 states and U.S. territories have finalized their individual “microplans” for distribution and administration, according to an Operation Warp Speed official. Read More
Yesterday, Pfizer and BioNTech disclosed that information pertaining to their regulatory submission for emergency-use approval of COVID-19 vaccine BNT162b2 was hacked on a European Medicines Agency (EMA) server containing the data. Read More